Patents by Inventor Gary Koppel

Gary Koppel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • {Beta}-Lactamyl vasopression V1a antagonists and methods of use
    Publication number: 20080113959
    Abstract: Novel 2-(azetidin-2-on-1-yl) alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl) alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: October 17, 2007
    Publication date: May 15, 2008
    Applicant: Azevan Pharmaceuticals, Inc.
    Inventor: Gary Koppel
  • {Beta}-Lactamyl vasopression V1a antagonists and methods of use
    Publication number: 20080090797
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: October 17, 2007
    Publication date: April 17, 2008
    Applicant: Azevan Pharmaceuticals, Inc.
    Inventors: Gary Koppel, Robert Bruns
  • [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use
    Publication number: 20080033165
    Abstract: Novel 2-(azetidin-2-on-1-yl) alkanedioic acid derivativies and 2-(azetidin-2-on-1-yl) alkoxyalkanoic acid derivativies are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: August 7, 2007
    Publication date: February 7, 2008
    Inventors: Gary Koppel, Robert Bruns
  • Neurotherapeutic composition and method therefor
    Publication number: 20070249523
    Abstract: Neurotherapeutically effective pharmaceutical compositions are described that include carboxypeptidase E inhibitors. One class of carboxypeptidase E inhibitors found to exhibit significant neurotropic activity are ?-lactam compounds, particularly penam and cephem ?-lactam antibiotics and non-antibiotic derivatives thereof.
    Type: Application
    Filed: February 28, 2007
    Publication date: October 25, 2007
    Inventors: Gary Koppel, Michael Chaney
  • NEUROTHERAPEUTIC TREATMENT FOR SEXUAL DYSFUNCTION
    Publication number: 20070093466
    Abstract: A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of ?-lactams, penicillin-binding protein, carboxypeptidase,. Such compounds, including particularly ?-lactam ring-containing compounds, can be used to formulate pharmaceutical formulations useful for improving sexual function.
    Type: Application
    Filed: November 21, 2006
    Publication date: April 26, 2007
    Inventor: Gary Koppel
  • 3-Substituted beta-lactamyl vasopressin v1a antagonists
    Publication number: 20060281728
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acids and derivatives thereof are described. Methods for using 2-(azetidin-2-on-1-yl)alkanedioic acids and derivatives thereof in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor are also described.
    Type: Application
    Filed: October 1, 2004
    Publication date: December 14, 2006
    Inventors: Christophe Guillon, Ned Heindel, Gary Koppel, Marvin Miller
  • Beta-lactamyl vasopressin V1a antagonists
    Publication number: 20060217364
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: May 30, 2006
    Publication date: September 28, 2006
    Inventors: Robert Bruns, Christophe Guillon, Ned Heindel, Gary Koppel, Marvin Miller